-
Ubrogepant
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Ubrogepant 1374248-77-7 Dec, 2027 Sep.28, 2035 estimated PV Completion – Oct, 2027 [Indication]
For the acute treatment of migraine with or without aura in adults.
-
Upadacitinib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Upadacitinib 1310726-60-3 40355 Aug.16, 2033 PV completion Upadacitinib Hemihydrate 2050057-56-0 40672 Aug.16, 2033 PV completion [Indication]
1. For the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
2. For the treatment of adult patients with active psoriatic arthritis (PsA).
3. For the treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (polyJIA).
4. For the treatment of adult patients with moderately to severely active Crohn’s disease (CD).